Tijaria Polypipes Ltd to Consider Q2 FY27 Results November 4

Tijaria Polypipes Ltd will consider unaudited standalone results for the quarter and half-year ended September 30, 2026, at its November 4 board meeting, following a ₹0.36 crore net loss and nil sales reported for the June 2026 quarter. The meeting is the next scheduled disclosure point for the company’s financial performance.

When will Tijaria Polypipes consider its September 2026 results?

Tijaria Polypipes will hold its Board of Directors meeting on November 4, 2026, at 3:00 PM to consider and approve its unaudited financial results for the quarter and half-year ended September 30, 2026. The board is also scheduled to consider the limited review report associated with the financial statements.

The company issued the board-meeting intimation on October 27. The planned approval is significant because it will provide the next official set of financial disclosures after the standalone results for the quarter ended June 30, 2026. No September-quarter financial figures were included in the meeting intimation.

The results are described as standalone and unaudited. A limited review report is to be placed before the board along with the results. Such a review is part of the quarterly financial reporting process and provides investors with the company’s formally approved disclosure for the period.

What is the trading-window restriction for Tijaria Polypipes shares?

Tijaria Polypipes has closed its trading window from October 1, 2026, and said it will reopen 48 hours after the September-quarter results are made public on November 4. The restriction applies around the release of unpublished price-sensitive information, including quarterly financial results.

The closure means designated persons covered by the company’s insider-trading compliance framework cannot trade in the company’s securities during the stated period. The company’s disclosure sets out the reopening condition rather than a separate calendar date, linking it to the public announcement of the results.

This is a routine governance measure for listed companies reporting financial results. For shareholders, the relevant event remains the release of the board-approved financial statements and limited review report after the meeting.

What did Tijaria Polypipes report in the June 2026 quarter?

Tijaria Polypipes reported nil sales and a standalone net loss of ₹0.36 crore for the quarter ended June 30, 2026, according to the quarterly data provided. Its profit before tax for the quarter was also a loss of ₹0.36 crore, while expenses were ₹0.10 crore.

The June-quarter data followed a net loss of ₹0.30 crore in the March 2026 quarter. The reported quarterly series shows nil sales across the periods presented from September 2023 through June 2026, except for ₹0.04 crore in June 2023 and ₹0.11 crore in March 2024.

The following table summarises the disclosed financial and meeting information. All absolute financial amounts are shown in ₹ crore.

How does the upcoming disclosure compare with earlier results?

The upcoming September 2026 results follow the board’s approval of the June 2026 standalone unaudited results on August 14, 2026, together with the limited review report. The board had earlier approved audited results for the quarter and year ended March 31, 2026, on May 26, 2026.

For the financial year ended March 31, 2026, the company reported a net loss of ₹1.2872 crore and nil revenue from operations. This compared with a net loss of ₹5.43 crore for the year ended March 2025, based on the reported financial summary. The March 2026 quarterly loss of ₹0.30 crore was lower than the ₹3.14 crore loss reported for the March 2025 quarter.

The June 2026 quarter then recorded a ₹0.36 crore loss, compared with ₹0.30 crore in the immediately preceding March quarter. Since reported sales remained nil, the next results release will be relevant for tracking whether the company reports any change in operating revenue, expenses, or losses.

Why does the November 4 meeting matter to investors?

The November 4 meeting matters because it will disclose Tijaria Polypipes’ financial position for the September quarter and the first half of the relevant reporting period. Investors will receive board-approved standalone numbers, supported by a limited review report, instead of relying on meeting notices or historical quarterly data.

The available figures show that the company has continued to report nil sales and net losses in recent periods. Therefore, the reported revenue from operations, expense pattern, profit or loss figure, and any disclosures accompanying the results will be key factual indicators for shareholders. The announcement itself does not provide a financial forecast or indicate any expected improvement in performance.

Conclusion

Tijaria Polypipes is scheduled to approve its standalone unaudited results for the quarter and half-year ended September 30, 2026, on November 4 at 3:00 PM. The meeting follows a June-quarter net loss of ₹0.36 crore and nil sales, while FY26 ended with a ₹1.2872 crore net loss and no operating revenue.

Investors should watch for the board-approved September-quarter and half-year figures, the limited review report, and the trading-window reopening 48 hours after the public results announcement. The source does not disclose a target, forecast, or operational plan ahead of the meeting.